This article first appeared on GuruFocus .
-
Total Income:INR447.8 crores, up 11.4% year-on-year from INR401.9 crores.
-
Gross Margin:52.1%, down from 53.2% in Q3 FY25.
-
EBITDA:INR85 crores with a margin of 19%.
-
Profit Before Tax:INR54.3 crores, compared to INR71.8 crores in Q3 FY25.
-
Quarterly EPS:INR31.5 per share.
-
Working Capital:145 days of sales.
-
CapEx Cash Outflow:INR254 crores for the nine months of FY26.
-
Free Cash Flow:Negative INR9.2 crores for the year.
-
Net Debt:Negative INR202.6 crores.
-
Warning! GuruFocus has detected 6 Warning Signs with XKRX:036570.
-
Is BOM:524558 fairly valued? Test your thesis with our free DCF calculator.
Release Date: February 09, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Neuland Laboratories Ltd ( BOM:524558 ) reported a total income of INR447.8 crores for Q3 FY26, marking an 11.4% increase year-on-year.
-
The company has successfully commercialized a new CMS molecule, with shipments expected to contribute to future revenues.
-
Neuland Laboratories Ltd ( BOM:524558 ) has expanded its capacity for CMS projects, which is expected to drive growth in the coming quarters.
-
The company is seeing increased interest from big pharma and biotech companies, particularly in its peptide manufacturing capabilities.
-
Neuland Laboratories Ltd ( BOM:524558 ) has maintained a strong net debt position, standing at negative INR202.6 crores, indicating financial stability.
Negative Points
-
The gross margin for Q3 FY26 decreased to 52.1% from 53.2% in the same quarter last year, primarily due to product mix changes.
-
EBITDA margin fell to 19% this quarter, impacted by increased overheads and labor costs.
-
There was a significant impact on revenue from Paliperidone due to operational issues at the customer end, affecting shipments.
-
The company's working capital has deteriorated due to higher inventories and uneven order flow, leading to higher receivables.
-
Free cash flow was negative INR9.2 crores for the year, despite securing substantial advances from customers.
Q & A Highlights
Q: Despite having a higher CDMO share this quarter, why have gross margins decreased? Does this mean CDMO's gross margins are lower than Prime API gross margins? A: No, the deduction is incorrect. The decrease in gross margins is due to the absence of shipments for a high-margin CMS product and some higher-margin GDS products like Paliperidone. The CMS margins are significantly higher than Prime products, and the absence of these specific products impacted the overall margin. - Davuluri Rao, CEO
Q: What is the status of the expanded capacity for a CDMO contract and the commercialization of a CMS project? A: The expansion of capacity for the CMS product has been completed, and ramp-up has started, though it will take another one or two quarters to fully pick up. The CMS molecule has been commercialized with some shipments at the end of the quarter, and more are expected in Q4 and beyond. - Davuluri Rao, CEO
Q: What gives optimism about Q4 and full-year FY26 outlook, given the in-line performance of Q3? A: The ramp-up is happening as planned, with significant shipments expected. However, due to the lumpiness of shipments, we are cautious about giving specific guidance. We remain optimistic about the medium-term horizon. - Davuluri Rao, CEO
Q: Can you elaborate on the traction from innovators for peptide molecules and the confidence in peptide CapEx? A: There is significant interest from innovators, with five or six peptide projects underway. Although these are early-stage, they indicate that Neuland is seen as a partner for peptide development. We aim to secure at least one commercial manufacturing arrangement for peptides by FY27. - Davuluri Rao, CEO
Q: What is the impact of the India-EU and India-US trade deals on Neuland Laboratories? A: The India-EU deal reduces tariffs on API imports, making Indian APIs more attractive to European pharma companies. The India-US deal does not directly benefit us as pharma has been exempt from tariffs, but it removes an overhang for the industry. - Davuluri Rao, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
